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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
proanthocyanidins from cranberry (Vaccinium macrocarpon Aiton) fruit 
and defence against bacterial pathogens in the lower urinary tract 
(ID 1841, 2153, 2770, 3328), “powerful protectors of our gums” (ID 1365), 




EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to proanthocyanidins from cranberry (Vaccinium macrocarpon Aiton) fruit and defence 
against bacterial pathogens in the lower urinary tract, “powerful protectors of our gums”, and “heart 
health”. The scientific substantiation is based on the information provided by the Member States in 
the consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The foods/food constituents that are the subject of the health claims are “Sqeez Cranberry Juice 
Drink”, “proanthocyanidins in cranberry juice”, “Vaccinium macrocarpon, oxycoccus (Common 
Name: Cranberry)”, “whole cranberry powder from North American Cranberry (Vaccinium 
macrocarpon) Early Black species”, and “cranberry extract powder (Vaccinium macrocarpon)”. The 
Panel notes that the composition and/or manufacturing process for these cranberry-derived food 
products are not specified in the information provided. The Panel considers that, whereas various food 
products derived from cranberry fruits, i.e. cranberry juice; diluted cranberry juice concentrate; 
cranberry juice cocktails; cranberry extracts, powders, and capsules, are not sufficiently characterised 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2102, EFSA-Q-2008-2574, EFSA-Q-2008-2886, 
EFSA-Q-2008-3232, EFSA-Q-2008-3503, EFSA-Q-2008-4060, adopted on 13 May 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. EFSA staff: Wolfgang Gelbmann for the support 
provided to this scientific opinion. 
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in relation to the claimed effects considered in this opinion, proanthocyanidins from cranberry 
(Vaccinium macrocarpon Aiton) fruit are sufficiently characterised.  
Defence against bacterial pathogens in the lower urinary tract 
The claimed effects are “urinary tract”, “health of the lower urinary tract”, and “reduce biofilms on 
uroepithelial cells”. The target population is assumed to be the general population. In the context of 
the proposed wordings, clarifications from Member States and references provided, it is assumed that 
the claimed effects refer to defence against bacterial pathogens in the lower urinary tract. The Panel 
considers that defence against bacterial pathogens in the lower urinary tract is a beneficial 
physiological effect.  
A claim on cranberry (Vaccinium macrocarpon Aiton) fruit products standardised by their 
proanthocyanidin content and reduction in the risk of urinary tract infections in women by inhibiting 
the adhesion of certain bacteria in the urinary tract has already been assessed with an unfavourable 
outcome. The Panel considers that the references provided for this claim did not provide any 
additional scientific data which could be used to substantiate the claim. 
On the basis of the data presented, the Panel concludes that the evidence provided is insufficient to 
establish a cause and effect relationship between the consumption of proanthocyanidins from 
cranberry (Vaccinium macrocarpon Aiton) fruit and defence against bacterial pathogens in the lower 
urinary tract. 
“Powerful protectors of our gums” 
The claimed effect is “powerful protectors of our gums”. The target population is assumed to be the 
general population.  
The claimed effect is not sufficiently defined, and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
“Heart health”  
The claimed effect is “heart health”. The target population is assumed to be the general population.  
The claimed effect is not sufficiently defined, and no further details were provided in the proposed 
wordings or clarifications provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
KEY WORDS 
Vaccinium macrocarpon Aiton, cranberry, proanthocyanidins, urinary tract, gums, heart, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The foods/food constituents that are the subject of the health claims are “Sqeez Cranberry Juice 
Drink”, “proanthocyanidins in cranberry juice”, “Vaccinium macrocarpon, oxycoccus (Common 
Name: Cranberry)”, “whole cranberry powder from North American Cranberry (Vaccinium 
macrocarpon) Early Black species”, and “cranberry extract powder (Vaccinium macrocarpon)”. 
In the information provided, a number of food products derived from two varieties of cranberry 
(Vaccinium macrocarpon Aiton and Vaccinium oxycoccos L.) fruit were mentioned i.e. cranberry 
juice; diluted cranberry juice concentrate; cranberry juice cocktails; cranberry extracts, powders, and 
capsules. The Panel notes that the composition and/or manufacturing process for these 
cranberry-derived food products are not specified in the information provided. The Panel also notes 
that no human studies have been provided using cranberry fruit products derived from V. oxycoccos L.  
The conditions of use related to some of these claims specify the amount of cranberry fruit products to 
be consumed in order to obtain the claimed effects in relation to their proanthocyanidin (PAC) 
content. The PAC fraction isolated from cranberries (V. macrocarpon Aiton) is a mixture of catechin 
and epicatechin oligomers of various molecular weights, and consists of predominantly procyanidin 
pentamers and tetramers containing at least one A-type linkage (Cunningham et al., 2002; Foo et al., 
2000).  
The Panel considers that whereas various food products derived from cranberry fruits, i.e. cranberry 
juice; diluted cranberry juice concentrate; cranberry juice cocktails; cranberry extracts, powders, and 
capsules, are not sufficiently characterised in relation to the claimed effects, PAC from cranberry 
(V. macrocarpon Aiton) fruit are sufficiently characterised.  
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2. Relevance of the claimed effect to human health 
2.1. Defence against bacterial pathogens in the lower urinary tract (ID 1841, 2153, 2770, 
3328) 
The claimed effects are “urinary tract”, “health of the lower urinary tract”, and “reduce biofilms on 
uroepithelial cells”. The Panel assumes that the target population is the general population. 
In the context of the proposed wordings, clarifications from Member States and references provided, 
the Panel assumes that the claimed effects refer to defence against bacterial pathogens in the lower 
urinary tract, which can be assessed in vivo as changes in the incidence of symptomatic urinary tract 
infections (UTIs). 
The Panel considers that defence against bacterial pathogens in the lower urinary tract is a beneficial 
physiological effect.  
2.2. “Powerful protectors of our gums” (ID 1365) 
The claimed effect is “powerful protectors of our gums”. The Panel assumes that the target population 
is the general population. 
The claimed effect is not sufficiently defined, and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.3. “Heart health” (ID 2499) 
The claimed effect is “heart health”. The Panel assumes that the target population is the general 
population. 
The claimed effect is not sufficiently defined, and no further details were provided in the proposed 
wordings or clarifications provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
3. Scientific substantiation of the claimed effect 
3.1. Defence against bacterial pathogens in the lower urinary tract (ID 1841, 2153, 2770, 
3328)  
The references provided for the scientific substantiation of the claim included several narrative 
reviews and monographs which did not provide original data for the scientific substantiation of the 
claim, and some human intervention studies which investigated the effects of food constituents other 
than PAC in cranberry fruit products (e.g. cranberry products in combination with warfarin or 
flurbiprofen, and mixtures of concentrates from cranberries and lingonberries) or addressed health 
outcomes (e.g. risk of urolithiasis) other than the claimed effect. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
A systematic review of randomised or quasi-randomised human intervention studies on the effects of 
cranberry and blueberry products on the incidence of symptomatic UTIs, 12 human intervention 
Proanthocyanidins from cranberry (Vaccinium macrocarpon Aiton) fruit related health claims 
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studies and one observational study on the effects of cranberry fruit products on the incidence of UTI, 
and 17 non-human studies on the mechanisms by which cranberry fruit products could exert the 
claimed effect were provided.  
A claim on cranberry (V. macrocarpon Aiton) fruit products standardised by their PAC content and 
reduction in the risk of UTIs in women by inhibiting the adhesion of certain bacteria in the urinary 
tract has already been assessed with an unfavourable outcome (EFSA, 2009). The scientific 
evaluation was based on the insufficient evidence provided by the applicant to establish a cause and 
effect relationship between the consumption of cranberry fruit products standardised by their PAC 
content and a reduction in the incidence of UTIs, and on the insufficient evidence provided to 
establish that the bacterial anti-adherence effects, which were shown in vitro, of cranberry fruit 
products in urine could predict the occurrence of a clinically relevant bacterial anti-adherence effect 
within the urinary tract in vivo in humans.  
Most of the references provided in the consolidated list which addressed the effects of cranberry 
(V. macrocarpon Aiton) fruit products standardised by their PAC content on the incidence of UTIs in 
different population sub-groups, and those which addressed the mechanisms by which cranberry fruit 
products could exert the claimed effect, were already considered in the previous opinion (EFSA, 
2009). 
Two additional references, which reported on human intervention studies and which were not 
considered in the previous opinion, were provided in the consolidated list (Bohbot, 2007; Jepson and 
Craig, 2008). The Panel notes that the methods used to diagnose UTI infection were not sufficiently 
described in the study by Bohbot (2007). It is also noted that all human trials analysed in the 
Cochrane review by Jepson and Craig (2008) were referenced also in the systematic review by Jepson 
and Craig (2007) which was considered in the previous opinion (EFSA, 2009). The Panel considers 
that these two references do not provide any additional scientific data which could be used to 
substantiate the claim. 
The Panel considers that the references provided for this claim did not provide any additional 
scientific data which could be used to substantiate the claim. 
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of proanthocyanidins from cranberry (V. macrocarpon Aiton) 
fruit and defence against bacterial pathogens in the lower urinary tract. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 Whereas various food products derived from cranberry fruits, i.e. cranberry juice; diluted 
cranberry juice concentrate; cranberry juice cocktails; cranberry extracts, powders, and 
capsules, are not sufficiently characterised in relation to the claimed effects considered in this 
opinion, proanthocyanidins from cranberry (Vaccinium macrocarpon Aiton) fruit are 
sufficiently characterised.  
Defence against bacterial pathogens in the lower urinary tract (ID 1841, 2153, 2770, 3328) 
 The claimed effects are “urinary tract”, “health of the lower urinary tract”, and “reduce 
biofilms on uroepithelial cells”. The target population is assumed to be the general 
population. In the context of the proposed wordings, clarifications from Member States and 
references provided, it is assumed that the claimed effect refers to defence against bacterial 
pathogens in the lower urinary tract. Defence against bacterial pathogens in the lower urinary 
tract is a beneficial physiological effect.  
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 A claim on cranberry (Vaccinium macrocarpon Aiton) fruit products standardised by their 
proanthocyanidin content and reduction in the risk of urinary tract infections in women by 
inhibiting the adhesion of certain bacteria in the urinary tract has already been assessed with 
an unfavourable outcome. The references provided for this claim did not provide any 
additional scientific data which could be used to substantiate the claim. 
 The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of proanthocyanidins from cranberry (V. macrocarpon Aiton) fruit and defence 
against bacterial pathogens in the lower urinary tract. 
“Powerful protectors of our gums” (ID 1365) 
 The claimed effect is “powerful protectors of our gums”. The target population is assumed to 
be the general population. The claimed effect is not sufficiently defined. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
“Heart health” (ID 2499) 
 The claimed effect is “heart health”. The target population is assumed to be the general 
population. The claimed effect is not sufficiently defined. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2102, 
EFSA-Q-2008-2574, EFSA-Q-2008-2886, EFSA-Q-2008-3232, EFSA-Q-2008-3503, EFSA-Q-2008-
4060). The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders.  
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Proanthocyanidins from cranberry (Vaccinium macrocarpon Aiton) fruit related health claims 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to proanthocyanidins from cranberry (Vaccinium 
macrocarpon Aiton) fruit, including conditions of use from similar claims, as proposed in the 
Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1365 Name of Food product: 
Sqeez Cranberry Juice 
Drink. 
Description of food in terms 
of food legislation 
categories: food not covered 
by specific food legislation. 
Was food on Irish market 
before 1st July 2007: Yes. 
Health benefits of food: 
Cranberries may be 
powerful protectors of 
our gums. 
Do benefits relate to a 
disease risk factor: No. 
Target group: All of the 
general population 
including children and 
adults. 
Exact wording of claim as it appears 
on product: More recently, emerging 
research suggests that cranberries 
may also be powerful protectors of 
our health in other areas of the body, 
such as the stomach, gums and even 
the heart. 
Is claim a picture: No. 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 1. Names of 
nutrient/other substances and Quantity in Average daily serving: 200ml cranberry juice. 
Weight of average daily food serving: 200 mililitre(s). Daily amount to be consumed to 
produce claimed effect: 200 mililitre(s). Number of food portions this equates to in everyday 
food portions: 1. Are there factors that could interfere with bioavailability: Yes. Please give 
reason: Storage beyond its shelf life. Length of time after consumption for claimed effect to 
become apparent: It is apparent immediately. Is there a limit to the amount of food which 
should be consumed in order to avoid adverse health effects: No 
Comments from Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
Authority of Ireland 
ID Food or Food constituent Health Relationship Proposed wording 
1841 Proanthocyanidins in 
cranberry juice. 
Urinary tract. Cranberry helps to inhibit the 
attachment of certain E-coli bacteria 
to the urinary tract. 
 
Conditions of use 
- Cranberry juice with 3.6 mg/100g, 7.2 mg/serving of proanthocyanidins. 
- pure cranberry juice in powder extract available in capsules or sachets (food supplement) 
dosage : 36mg proanthocyanidins (PAC) per day measured by DMAC method equivalent in 
dosage and characterization to the product shown to be effective in clinical studies (i.e. 300 
ml of cranberry juice cocktail) 
ID Food or Food constituent Health Relationship Proposed wording 
2153 Vaccinium macrocarpon, 
oxycoccus (Common Name 
: Cranberry). 
Health of the lower 
urinary tract. 
Clarification provided 
Improves urinary tract 
Helps to maintain the health of the 
urinary system / contributes to urinary 
tract health / has a beneficial effect on 
the urinary system / canneberge or 
Vaccinium macrocarpon by 
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unfavourable bacteria in 
the urinary tract. 
Daily consumption of 36 
mg PAC of cranberry 
vaccinium macrocarpon 
(measured by DMAC 
method) and 
contributing effect to 
decrease the adherence 
of certain uropathogenic 
P-fimbriated E.coli to 
the walls of the urinary 
tract. 
Helps to preserve the 
urinary tract's integrity 
thanks to its 
antimicrobial effect. 
concentrated juices, by food 
supplements and a juice 
cocktail/nectar). 
Conditions of use 
- owoce/zwykle konsumowane jako tradycyjny artykuł żywnościowy w normalnej diecie/ 
równowartość 36 mg proantocyjanidyn na dzień lub minimum 400 mg owocu żurawiny na 
dzień. 
- 300 bis 400 mg - auf zwei Einnahmen täglich verteilt (standardisierter Extrakt) –
Erwachsene. 
- Frucht, Positive Studienergebnisse erst ab 200 mg Cranberry-konzentrat/ Tag. 
- Formen: 100 % Fruchtsaft, Fruchtsaftkonzentrat, Extrakte aus der ganzen Frucht oder dem 
Fruchtsaft. 
- 360-600 mg  
- Fruit / The equivalent of 36 mg of proanthocyanidines per day. 
- Food supplement containing 500 mg/day of cranberry extract (Vaccinium macrocarpon). 
The cranberry extract is the patented CranMax extract. 
- Jus du fruit. 6 x 250 mg/jour. 
- Vaccinium marcrocarpon–Standardisierter Extrakt auf DEV 25:1–Tagesdosis Cranberry: 
1200 mg–Erwachsene. 
- 450 mg cranberry solids (500 mg CranMax™ /day). 
- Product ready-to-drink (diluted juice, nectar or syrup) containing 11.3 g of juice concentrate; 
used daily over 12 month. 
- Vaccinium marcrocarpon–Standardisierter Extrakt auf DEV 25:1–Tagesdosis Cranberry: 
1200 mg–Erwachsene 
- Pure cranberry juice in powder extract available in capsules or sachets (food supplement) 
dosage: 36 mg proanthocyanidins (PAC) per day measured by DMAC method equivalent in 
dosage and characterization to the product shown to be effective in clinical studies (i.e. 300 
ml of cranberry juice cocktail). 
- Fruit / 400mg of dry extract per day. 
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ID Food or Food constituent Health Relationship Proposed wording 
2499 Vaccinium macrocarpon, 
oxycoccus (Cranberry). 
Heart health. Helps maintain a healthy heart and 
blood vessels. 
Conditions of use 
- Concentrated cranberry (12:1): 140 mg / Concentrated cranberry juice: 2.7 g / Used as part 
of a multi-botanical combination. 
- Fruit. The equivalent of minimum 15 ml of cranberry juice or 800 mg of cranberry solids per 
day. 
Comments from Member States 
Contributes to vascular health, which in turn helps to maintain a healthy heart. 
ID Food or Food constituent Health Relationship Proposed wording 
2770 Food supplement/Food 
ingredient: Whole cranberry 
powder from North 
American Cranberry 
(Vaccinium macrocarpon) 
Early Black species. 
Health of the lower 
urinary tract. 
Helps to maintain the health of the 
urinary system. 
Contributes to urinary tract health. 
Has a beneficial effect on the urinary 
system. 
Helps to eliminate pathogenic 
bacteria from urinary tract. 
Conditions of use 
- 500 mg/day. 
- Fruit / Usual consumption als traditional foodstuff in a normal diet / The equivalent of 36 
mg of proanthocyanides per day or a minimum of 400 mg of cranberry solids per day. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3328 Cranberry extract powder 
(Vaccinium macrocarpon). 
Reduce biofilms on 
uroepithelial cells. 
Helps to increase growth of 
beneficial microflora. 
Conditions of use 
- 500 mg of cranberry powder per day. 
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GLOSSARY AND ABBREVIATIONS 
PAC Proanthocyanidins 
UTI Urinary tract infection 
 
